Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients

Table 1 Antihypertensive therapy at baseline and during follow-up

		Baseline		after switch		after 3 month		after 9 month
		Metab (-)	Metab (+)	Metab (-)	Metab (+)	Metab (-)	Metab (+)	Metab (-)	Metab (+)
Substance classes
none	%	4.9	2.7	0.0	0.0	0.0	0.0	0.0	0.0
ACE-inhibitors	%	48.2	59.3*	3.7	7.7*	3.5	7.6*	3.5	7.0*
Alpha-blockers	%	3.2	4.1**	1.6	2.6*	1.5	2.6*	1.5	2.6*
ARBs	%	4.0	4.7	98.9	99.8*	97.6	97.7	91.9	92.0
Beta-blockers	%	44.3	49.3*	25.9	34.8*	25.3	33.7*	24.2	31.3*
Diuretics	%	30.7	47.8*	7.0	14.4*	6.5	13.6*	6.0	12.4*
Calcium antagonists	%	27.5	36.4*	13.3	22.7*	13.4	23.0*	13.0	21.8*
Irbesartan 75 mg	%	< 0.1	0.0	0.3	0.2	0.3	0.1**	0.3	0.1**
Irbesartan 150 mg	%	0.5	0.4	11.0	5.8*	8.0	3.7*	7.5	3.2*
Irbesartan 300 mg	%	0.1	0.2	29.8	22.0*	28.2	19.8*	25.2	17.9*
Irbesartan 150 mg/12,5 mg HCTZ	%	< 0.1	0.1	10.8	9.1**	8.9	6.6*	8.4	6.1*
Irbesartan 300 mg/12,5 mg HCTZ	%	0.1	< 0.1	46.0	62.1*	50.4	66.0*	48.2	62.6*

Met (+) – Patients with the metabolic syndrome (doctors' diagnosis); Met (-) – Patients without the metabolic syndrome; statistical test applied: Chi²-test; * p < 0.0001 vs. patients without MS; ** p < 0.01 vs. patients without MS

ISSN: 1475-2840